Effects of brain IKKß gene silencing by small interfering RNA on P-glycoprotein expression and brain damage in the rat kainic acid-induced seizure model

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 4, 2014, Pages 661-672

  Yu, Nian ^a   Liu, Hao ^b   Zhang, Yan Fang ^a   Su, Ling Ying ^a   Liu, Xin Hong ^a   Li, Le Chao ^a   Hao, Jin Bo ^a   Huang, Xian Jing ^a   Di, Qing ^a  

^a THE AFFILIATED BRAIN HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Epilepsy; Inhibitory B kinase subunit ; Multidrug resistance; Nuclear factor kappa B; P glycoprotein

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KAINIC ACID; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; I KAPPA B KINASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CELL COUNTING; CONTROLLED STUDY; DENSITOMETRY; DENTATE HILUS; ELECTROENCEPHALOGRAPHY; GEL MOBILITY SHIFT ASSAY; GENE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSCRIPTION; HIPPOCAMPAL CA3 REGION; I KAPPA B KINASE BETA GENE; IMMUNOHISTOCHEMISTRY; MALE; MICROPHOTOGRAPHY; MRNA EXPRESSION ASSAY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEIZURE; WESTERN BLOTTING; ANIMAL; BRAIN; DISEASE MODEL; GENE EXPRESSION; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; SPRAGUE DAWLEY RAT;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; GENE EXPRESSION; I-KAPPA B KINASE; KAINIC ACID; MALE; NEURONS; NF-KAPPA B; P-GLYCOPROTEIN; RATS, SPRAGUE-DAWLEY; RNA INTERFERENCE; RNA, SMALL INTERFERING; SEIZURES; TRANSCRIPTION, GENETIC;

EID: 84904514354     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113129990106     Document Type: Article

References (51)

1. Kwan P, Sander JW. The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry 2004; 75(10): 1376-81.
2. Cascorbi I. In: Pharmacogenomics of Human Drug Transporters: Clinical Impacts; Ishikawa T, Kim RB, König J, Eds.; John Wiley & Sons, USA 2013; ch 12: pp. 271-93.
3. Hughes JR. One of the hottest topics in epileptology: ABC proteins. Their inhibition may be the future for patients with intractable seizures. Neurol Res 2008; 30(9): 920-5.
4. Li Y, Yuan H, Yang K, Xu W, Tang W, Li X. The structure and functions of P-glycoprotein. Curr Med Chem 2010; 17(8): 786-800.
5. Löscher W. Animal models of drug-resistant epilepsy. Novartis Found Symp 2002; 243: 149-59.
6. Tate SK, Sisodiya SM. Multidrug resistance in epilepsy: a pharmacogenomic update. Expert Opin Pharmacother 2007; 8(10): 1441-9.
7. Bartels AL, de Klerk OL, Kortekaas R, de Vries JJ, Leenders KL. 11C-verapamil to assess P-gp function in human brain during aging, depression and neurodegenerative disease. Curr Top Med Chem 2010; 10(17): 1775-84.
8. Hartz AM, Notenboom S, Bauer B. Signaling to P-glycoprotein-A new therapeutic target to treat drug-resistant epilepsy? Drug News Perspect 2009; 22(7): 393-7.
9. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol 2011; 7(1): 31-40.
10. Maroso M, Balosso S, Ravizza T, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 2010; 16(4): 413-9.
11. Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005; 46(11): 1724-43.
12. Roberts DJ, Goralski KB. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opin Drug Metab Toxicol 2008; 4(10): 1-20.
13. Vallabhapurapu S, Karin M. Regulation and function of NFkappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27: 693-733.
14. Israël A. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb Perspect Biol 2010; 2(3): 1-14.
15. O'Neill L.A. Counter-regulation in the IKK family. Biochem J 2011; 434(1): e1-2.
16. Palkowitsch L, Leidner J, Ghosh S, Marienfeld RB. Phosphorylation of serine 68 in the IkappaB kinase (IKK)-binding domain of NEMO interferes with the structure of the IKK complex and tumor necrosis factor-alpha-induced NF-kappaB activity. J Biol Chem 2008; 283(1): 76-86.
17. Bamborough P, Morse MA, Ray KP. Targeting IKKβ for the treatment of rheumatoid arthritis. Drug News Perspect 2010; 23(8): 483-90.
18. Schmid JA, Birbach A. IkappaB kinase beta (IKKbeta/IKK2/IKBKB)--a key molecule in signaling to the transcription factor NF-kappaB. Cytokine Growth Factor Rev 2008; 19(2): 157-65.
19. Yu N, Di Q, Liu H, et al. Nuclear factor-kappa B activity regulates brain expression of P-glycoprotein in the kainic acid-induced seizure rats. Mediat Inflamm 2011; 670613.
20. The Ministry of Science and Technology of the People's Republic of China, Guidance Suggestions for the Care and Use of Laboratory Animals. 2006
21. Wan X, Fan L, Hu B, et al. Small interfering RNA targeting IKKβ prevents renal ischemia-reperfusion injury in rats. Am J Physiol Renal Physiol 2011; 300(4): F857-63.
22. Austin RL, Rune A, Bouzakri K, Zierath JR, Krook A. iRNAmediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle. Diabetes 2008; 57(8): 2066-73.
23. Paxino G, Watson C. The Rat Brain in Sterotaxic Coordinates; 5th edn.; Elsevier Academic Press, London, UK 2005.
24. Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972; 32(3): 281-94.
25. Galic MA, Riazi K, Henderson AK, Tsutsui S, Pittman QJ. Viral-like brain inflammation during development causes increased seizure susceptibility in adult rats. Neurobiol Dis 2009; 36(2): 343-51.
26. Lasson W. Mechanisms of drug resistance in epilepsy. Przgl Leκ 2006; 63(11): 1218-20.
27. Lazarowski A, Czornyj L. Potential role of multidrug resistant proteins in refractory epilepsy and antiepileptic drugs interactions. Drug Metabol Drug Interact 2011; 26(1): 21-6.
28. Margineanu DG, Klitgaard H. Mechanisms of drug resistance in epilepsy: relevance for antiepileptic drug discovery. Expert Opin Drug Discov 2009; 4(1): 23-32.
29. van Vliet EA, Zibell G, Pekcec A, et al. COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology 2010; 58(2): 404-12.
30. Friedman A, Dingledine R. Molecular cascades that mediate the influence of inflammation on epilepsy. Epilepsia 2011; 52(Suppl 3): 33-9.
31. Aronica E, Crino PB. Inflammation in epilepsy: clinical observations. Epilepsia 2011; 52(Suppl 3): 26-32.
32. Bauer B, Hartz AM, Miller DS. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol 2007; 71(3): 667-75.
33. Hartz AM, Bauer B, Fricker G, Miller DS. Rapid modulation of Pglycoprotein-mediated transport at the blood-brain barrrer by tumor necrosis factor-alpha and lipopolysaccharide. Mol Pharmacol 2006; 69(2): 462-70.
34. Lubin FD, Ren Y, Xu X, Anderson AE. Nuclear factor-kappa B regulates seizure threshold and gene transcription following convulsant stimulation. J Neurochem 2007; 103(4): 1381-95.
35. HuangFu WC, Matsumoto K, Ninomiya-Tsuji J. Osmotic stress blocks NF-kappaB-dependent inflammatory responses by inhibiting ubiquitination of IkappaB. FEBS Lett 2007; 581(29): 5549-54.
36. Chen JH, Huang SM, Chen CC, et al. Ghrelin induces cell migration through GHS-R, CaMKII, AMPK and NF-kappaB signaling pathway in glioma cells. J Cell Biochem 2011; 112(10): 2931-41.
37. Jost D, Nowojewski A, Levine E. Small RNA biology is systems biology. BMB Rep 2011; 44(1): 11-21.
38. Blow N. Small RNAs: delivering the future. Nature 2007; 450(7172): 1117-20.
39. Zibell G, Unkrüer B, Pekcec A, et al. Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 2009; 56(5): 849-55.
40. Bauer B, Hartz AM, Pekcec A, et al. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol 2008; 73(5): 1444-53.
41. Holtman L, van Vliet EA, Edelbroek PM, Aronica E, Gorter JA. Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy. Epilepsy Res 2010; 91(1): 49-56.
42. Zhang HL, Xu M, Wei C, et al. Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-κB signaling pathway. Neuroscience 2011; 176: 381-95.
43. Soerensen J, Pekcec A, Fuest C, Nickel A, Potschka H. Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model. Epilepsy Res 2009; 87(2-3): 177-83.
44. Cho IH, Hong J, Suh EC, et al. Role of microglial IKKbeta in kainic acid-induced hippocampal neuronal cell death. Brain 2008; 131(Pt 11): 3019-33.
45. Wajant H, Scheurich P. TNFR1-induced activation of the classical NF-κB pathway. FEBS J 2011; 278(6): 862-76.
46. Gantke T, Sriskantharajah S, Ley SC. Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinase. Cell Res 2011; 21(1): 131-45.
47. Shen RR, Hahn WC. Emerging roles for the non-canonical IKKs in cancer. Oncogene 2011; 30(6): 631-41.
48. Hartz AM, Bauer B. Regulation of ABC transporters at the bloodbrain barrier: new targets for CNS therapy. Mol Interv 2010; 10(5): 293-304.
49. Kuteykin-Teplyakov K, Brandt C, Hoffmann K, Löscher W. Complex time-dependent alterations in the brain expression of different drug efflux transporter genes after status epilepticus. Epilepsia 2009; 50(4): 887-97.
50. Izawa A, Schatton T, Frank NY, et al. A novel in vivo regulatory role of P-glycoprotein in alloimmunity. Biochem Biophys Res Commun 2010; 394(3): 646-52.
51. Kooij G, Backer R, Koning JJ, et al. P-glycoprotein acts as an immunomodulator during neuroinflammation. PLoS One 2009; 4(12): e8212.